The sensitivity analysis revealed that triglyceride results were unstable due to a single study, whereas the remaining results were very stable. In available RCTs, no statistically significant differences were observed between anti-TNF therapy and control treatments for conventional cardiovascular risk markers in patients with RA. The gene discussed is TNF; the disease is rheumatoid arthritis.